Skye Bioscience (SKYE)
Developing an investigational peripheral cannabinoid-receptor antibody for obesity.
Something off on this page? Send us feedback.
Develops nimacimab, an investigational antibody for obesity and related metabolic disease, as a pre-commercial research-and-development company. Progress depends on clinical evidence, regulatory advancement, outsourced manufacturing, and financing; nimacimab is the sole disclosed clinical-stage asset.
Develops nimacimab, an investigational monoclonal antibody intended to inhibit a cannabinoid receptor outside the central nervous system for obesity and related metabolic disease. Its sole disclosed clinical-stage asset is being evaluated in the CBeyond study as monotherapy and alongside semaglutide, while a small sponsor organization coordinates U.S. trial sites, translational research, regulatory preparation, and outsourced manufacturing.
Operates as a pre-commercial pharmaceutical research-and-development business with no approved or marketed drugs and no product revenue, supported principally by equity capital and cash on hand. The tested monotherapy regimen did not show the intended weight-loss effect, directing further work toward higher-dose characterization; the combination path depends on access to semaglutide, further trials, regulatory interaction, manufacturing scale-up, and demonstration of safety and efficacy.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.1M · Total debt $35.7K · Total assets $11.0M · Shareholders' equity −$497.3K
- Revenue
- $0
- Operating income
- −$11.1M
- Net income
- −$10.8M
No dividends on record.
| Institutions45 holders · as of Jun 30, 2026 | 45.24% | 2.00M shares | |
| Insiders6 holders · as of Aug 20, 2026 | 31.92% | 1.41M shares | |
| Otherremainder | 22.84% | 1.01M shares |
4.43M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
5Am Venture Management, LLCInstitution | 27.33% | 9.68M | 13Fas of Jun 30, 2026 |
Andrew J. SchwabInsiderdirector, 10 percent owner | 26.27% | 1.16M | Form 4filed Aug 20, 2026 ↗ |
Versant Venture Management, LLCInstitution | 5.67% | 2.01M | 13Fas of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 4.45% | 1.58M | 13Fas of Jun 30, 2026 |
Punit DhillonInsiderdirector, officer: Chief Executive Officer | 4.01% | 177,478 | Form 4filed Aug 7, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 20, 2026 | 5AM Partners VII, LLC | 10 percent owner | −7,700 | $0.3200 |
| Aug 19, 2026 | 5AM Partners VII, LLC | 10 percent owner | −68,140 | $0.3500 |
| Aug 18, 2026 | 5AM Partners VII, LLC | 10 percent owner | −300,000 | $0.3800 |
| Aug 20, 2026 | Andrew J. Schwab | director, 10 percent owner: | −7,700 | $0.3200 |
| Aug 19, 2026 | Andrew J. Schwab | director, 10 percent owner: | −68,140 | $0.3500 |
- Novo Nordisk (ADR)
Direct CB1 rival and semaglutide benchmark in obesity.
- Eli Lilly
Commercial efficacy benchmark across injectable obesity care.
- Corbus Pharmaceuticals
Direct peripheral-CB1 obesity rival with a small molecule.
- Viking Therapeutics
Late-stage injectable obesity challenger.
- Structure Therapeutics (ADR)
Oral GLP-1 challenger in obesity treatment.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Skye Bioscience | $1.88 | +1.62% | $8.1M | — | — | — | — |
| Novo Nordisk (ADR) | $47.44 | +1.47% | $207.69B | 11.5 | 18.9 | 4.1 | +0.0% |
| Eli Lilly | $1,167.77 | +0.72% | $1.09T | 38.9 | 28.4 | 13.7 | +47.7% |
| Corbus Pharmaceuticals | $11.46 | +1.60% | $212.7M | — | — | — | — |
| Viking Therapeutics | $32.98 | −1.55% | $3.91B | — | — | — | — |
| Structure Therapeutics (ADR) | $47.80 | +0.06% | $2.75B | — | — | — | — |
| Median | 25.2 | 23.6 | 8.9 | +23.9% |